Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9252W HIGH $5.96
Volume
218.02 K
Value Traded
184.78 K
Short % Float
16.78%
+7.56%Week
+23.08%1 Month
-2.66%3 Month
+21.33%6 Month
-99.71%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
341.10 M
EPS (TTM)
-0.12
P/E Ratio
-
Ent. Value
328.88 M
Total Shares
133.24 M
Float Shares
5.46 M
Insiders
96.45%
Institutions
0.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INDP Catalyst Timeline
Dated clinical, regulatory and corporate events for Indaptus Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Indaptus Therapeutics, Inc.
203Total events
0Upcoming
23Tier-1 (high impact)
2021 to 2026Coverage
Event history 50
▼Enrollment PausedDecoy20DiscontinuedTrial
Discontinued further enrollment in Decoy20 combination study
▼Program DiscontinuationDecoy20DiscontinuedCorporate
Reduced activities for further development of Decoy20
▲Partnership / LicenseCorporate
Began research collaboration in neurological disorders and sleep
▼Enrollment PausedDecoy20DiscontinuedTrial
Discontinued further enrollment in Decoy20 combination study
▼Program DiscontinuationDecoy20DiscontinuedCorporate
Reduced activities for further development of Decoy20
▲Partnership / LicenseCorporate
Began research collaboration in neurological disorders and sleep
neurological disorders and sleepsource ↗
▲Partnership / LicenseCorporate
Began research collaboration in neurological disorders and sleep
neurological disorders and sleepsource ↗
●Equity OfferingCorporate
Conversion of Series AA and Series AAA preferred stock into common stock
◆Timing GuidancePresentation
Stockholder approval expected for conversion of preferred shares
◆Runway Guidance UpdateCorporate
Cash and cash equivalents of $5.8 million expected to support operations into Q1 2026
▼Equity OfferingCorporate
Indaptus enters into $6 million securities purchase agreement with David E. Lazar for convertible preferred stock
◆Management ChangeCorporate
Avraham Ben-Tzvi joins Board; Hila Kara and Dr. Robert Martell step down
◆Timing GuidanceDecoy20DiscontinuedPresentation
Expects to share more data from combination trial by end of 2025
cancersource ↗
◆Oral PresentationPresentation
CSO Dr. Michael Newman presents at 3rd Donor Selection & Cell Source Summit
▲Enrollment CompleteDecoy20DiscontinuedTrial
Safety Lead-In cohort enrollment completed with six evaluable participants dosed with Decoy20 and tislelizumab
cancersource ↗
▼Enrollment PausedDecoy20DiscontinuedTrial
Enrollment paused pending additional efficacy evaluations and assessment of next development options
cancersource ↗
▲Safety Data UpdateDecoy20DiscontinuedClinical Data
Safety Review Committee determined Decoy20 and tislelizumab combination appears tolerable at current dose and schedule
cancersource ↗
◆Oral PresentationPresentation
Corporate overview presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲First Patient DosedDecoy20DiscontinuedTrial
First patient dosed in combination therapy cohort with tislelizumab
urothelial cancer with liver metastasessource ↗
●Enrollment UpdateDecoy20DiscontinuedTrial
Monotherapy portion completed; 7 patients initiated in combination cohort
urothelial cancersource ↗
▲Topline ReadoutDecoy20DiscontinuedClinical Data
Partial Response observed in monotherapy patient with urothelial cancer and liver metastases
urothelial cancer with liver metastasessource ↗
▼Equity OfferingCorporate
Raised approximately $2.3 million gross proceeds through at-the-market facility in September 2025
▼Equity OfferingCorporate
Additional sale of $3.4 million in private placement of convertible notes and warrants
▲First Patient DosedDecoy20DiscontinuedTrial
First patient dosed in Phase 1b/2 combination study of Decoy20 with tislelizumab
solid tumorssource ↗
▼Reverse Stock SplitCorporate
One-for-28 reverse stock split approved by Board, effective after market close June 26, 2025
▲First Patient DosedDecoy20DiscontinuedTrial
First patient dosed in Phase 1b/2 combination study of Decoy20 with tislelizumab
advanced solid tumorssource ↗
▼Equity OfferingCorporate
Raised $5.7 million via private placement of convertible notes and warrants
◆Oral PresentationPresentation
Dr. Michael Newman to present at 6th Annual Cytokine-Based Drug Development Summit
▲Enrollment CompleteDecoy20DiscontinuedTrial
Enrollment completed for weekly dosing arm of Decoy20 Phase 1 trial (32 patients enrolled)
cancersource ↗
▲Biomarker DataDecoy20DiscontinuedClinical Data
New data: weekly Decoy20 leads to broad blood-based immune cell trafficking
cancersource ↗
▲Trial InitiationDecoy20DiscontinuedTrial
Initiated new arm of Phase 1b/2 trial evaluating Decoy20 in combination with tislelizumab
cancersource ↗
▲Trial InitiationDecoy20DiscontinuedTrial
Initiation of Phase 1 combination study of Decoy20 with tislelizumab
solid tumorssource ↗
▲Enrollment MilestoneDecoy20DiscontinuedTrial
Enrolled more than 20 patients in weekly dosing cohort
cancersource ↗
▲Biomarker DataDecoy20DiscontinuedClinical Data
Initial data: Decoy20 at 30 million cell dose well-tolerated, stable disease, short-term increases in cytokines/chemokines
cancersource ↗
◆Oral PresentationPresentation
Dr. Michael Newman presents at 10th Annual Innate Killer Summit
cancersource ↗
▲Patent GrantedIP / Competition
Patent approvals in China, Japan, and Israel for Decoy platform covering HBV and HIV
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV)source ↗
Past FDA Catalysts and PDUFA Decisions
How INDP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Decoy20 (combination with PD-1 checkpoint inhibitor tislelizumab) | Phase 1b/2 data readout | Phase 1b/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$34M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 88%
Micro Cap(rank 579 of 658)
Percentile Rank
Indaptus Therapeutics, Inc. faces pipeline headwinds (23/100), with $190M risk-adjusted pipeline value, led by Decoy20 in Solid Tumor, Adult (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Decoy20 Small moleculeNCT05651022 | Solid Tumor, Adult | Phase 1 | ACTIVE NOT_RECRUITING | 120 | Sep 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every INDP program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lazar David E.Director | Sell | -196,800 103,200 held | $0.00 | 03/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INDP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in INDP for Q2 2026. | ||||
INDP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INDP ranks across every disease it competes in
Competitive Position is a premium feature
See how INDP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINDP News
INDPIndaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported its financial results for Q2 2026, highlighting a strengthened balance sheet due to a $12 million private placement. The company has discontinued its Decoy20 clinical study and has no active development programs. However, it has initiated a new research collaboration focusing on neurological disorders and sleep.
Read more →INDP▼ -9.1%on this news· ran to -30% by day 3
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported its financial results for Q1 2026, highlighting a net loss of approximately $2.5 million, down from $4.5 million in Q1 2025. The company is undergoing a management transition and reassessing its development priorities and resource allocation. Additionally, it has completed the conversion of preferred stock into common stock, but faces challenges in raising capital for future operations.
Read more →INDP▲ +6.7%on this news
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Therapeutics has entered a $6 million securities purchase agreement with investor David E. Lazar, who will also serve as Co-CEO and Chairman. The agreement involves the issuance of non-voting convertible preferred stock, pending stockholder approval. The company aims to leverage Lazar's expertise to explore strategic opportunities and enhance shareholder value.
Read more →INDP▼ -9.6%on this news· ran to -30% by day 3
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics announced that Dr. Michael Newman will present at the Donor Selection & Cell Source Summit in San Diego on November 19-20, 2025. His presentation will focus on new research related to the company's Decoy platform, which aims to enhance the potency of donor-derived immune cell therapies. This platform employs killed bacteria to induce and activate key immune cells, addressing challenges in allogeneic immunotherapy. The summit will highlight critical topics related to donor screening and process standardization in the expanding field of cell therapy.
Read more →INDP▲ +6.3%on this news· ran to -17% by day 3shared move
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported its third quarter 2025 financial results, highlighting the completion of a Safety Lead-In cohort for its combination therapy, Decoy20 with tislelizumab. While some participants showed stable disease, enrollment is paused for further efficacy evaluations. The company raised $2.3 million to strengthen its financial position as it continues its Phase 1 study.
Read more →INDP▼ -28.4%on this news· ran to -45% by day 3
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics provided updates on its INDP-D101 clinical trial, reporting a Partial Response in a patient with liver metastases from urothelial cancer using Decoy20 monotherapy. The combination therapy with PD-1 inhibitor tislelizumab is underway, with initial safety results showing mixed outcomes. The company also secured $5.7 million in funding to support its clinical efforts.
Read more →INDP▼ -14.6%on this news· ran to -50% by day 3shared move
Indaptus Therapeutics Provides Clinical Update Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases
Indaptus Therapeutics has provided a clinical update on its Decoy20 therapy, highlighting a Partial Response in a patient with urothelial cancer during the monotherapy study. The company is also moving forward with a combination study alongside PD-1 inhibitor tislelizumab, where initial safety assessments reveal stable disease in one patient out of three evaluable patients. Despite these developments, disease progression was noted in the other patients, raising concerns. Additionally, Indaptus has strengthened its financial position by raising approximately $5.7 million through the sale of convertible promissory notes.
Read more →INDP▼ -12.2%on this news· ran to -53% by day 3shared move
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Indaptus Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Jeffrey A. Meckler will provide a corporate overview and is available for one-on-one meetings. The event will be accessible via a live webcast, with a replay available for 90 days post-event.
Read more →INDPIndaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress -
Indaptus Therapeutics has reported its financial results for Q2 2025, highlighting significant clinical advancements, including the initiation of a Phase 1b/2 trial for its Decoy20 product combined with the PD-1 inhibitor tislelizumab. The company raised $5.7 million through a convertible note placement to support its clinical programs. While Indaptus is making progress in its immunotherapy efforts, it continues to face rising operational costs and has recorded a loss per share. Nonetheless, the leadership remains focused on executing their clinical strategy and expects to share initial trial data later this year.
Read more →INDP▲ +5.9%on this news
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics, Inc. has announced an additional sale of $3.4 million in convertible notes and warrants, bringing the total raised to $5.7 million. The funds will be utilized for research and development, particularly for a Phase 1b/2 clinical trial. The notes will mature in July 2026 and have a 6% interest rate.
Read more →INDP▼ -18.3%on this news
Indaptus Therapeutics Announces Reverse Stock Split
Indaptus Therapeutics has announced a one-for-twenty-eight reverse stock split effective after trading on June 26, 2025. This decision aims to increase the per share price to comply with Nasdaq listing requirements and attract institutional investors. Stockholders will receive cash for any fractional shares, and the total outstanding shares will decrease significantly.
Read more →INDPIndaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics, Inc. has announced the successful completion of a private placement, raising approximately $2.3 million through the sale of convertible promissory notes and warrants. This effort is part of a larger initiative aiming for up to $5 million in gross proceeds to fund research and development activities. The transaction is led by a healthcare-focused institutional investor, emphasizing confidence in the company's innovative cancer and viral infection treatments. The proceeds from the offering are also intended for working capital and general corporate purposes.
Read more →INDPIndaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics has initiated the expansion arm of its Phase 1b/2 clinical trial, dosing the first patient with Decoy20 in combination with the PD-1 inhibitor tislelizumab. This trial aims to evaluate safety and early anti-tumor activity in patients with advanced solid tumors. The combination is expected to enhance immune responses, particularly in patients who have not previously benefited from checkpoint inhibitors.
Read more →INDPIndaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics announced its first quarter 2025 financial results, highlighting advancements in its clinical trials and research programs. The company has initiated an expansion arm of the Phase 1b/2 clinical trial for Decoy20 in combination with Tislelizumab, focusing on safety and anti-tumor activity. Despite a decrease in cash reserves and rising expenses related to research and development, the company reported encouraging safety outcomes and beneficial early signs from clinical data. Additionally, Indaptus enhanced its intellectual property portfolio with new patents in vital markets.
Read more →INDPIndaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
Indaptus Therapeutics announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will chair and speak at the 6th Annual Cytokine-Based Drug Development Summit. He will present on 'Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy' and lead discussions on pre-clinical models. This reflects the growing recognition of Indaptus's novel approaches in immunotherapy.
Read more →INDP▲ +8%on this news
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
Indaptus Therapeutics has announced that its Chief Medical Officer, Dr. Roger Waltzman, will moderate a panel at the upcoming CMO360 Summit in Boston. The panel, focusing on clinical operations and trial efficiency, emphasizes the company's commitment to improving clinical trial management. CEO Jeffrey Meckler expressed optimism about the event's recognition of their approach. The CMO360 Summit serves as a significant networking platform for biotech Chief Medical Officers, showcasing initiatives to advance medicine development and delivery.
Read more →INDPIndaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Indaptus Therapeutics has reported positive findings from its Phase 1 trial of Decoy20, noting that the treatment was well-tolerated and showed early clinical benefits in over 20 patients. Weekly dosing resulted in significant immune system activation, with observable changes in immune cell trafficking. The company aims to enhance cancer treatment through both innate and adaptive immune responses. Future trials will explore Decoy20's safety and effectiveness in combination with existing therapies like BeiGene's PD-1 inhibitor.
Read more →INDPIndaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics has launched a new expansion arm of its Phase 1b/2 clinical trial to investigate the combination of its therapy Decoy20 with BeiGene's PD-1 inhibitor, tislelizumab. The trial aims to assess safety, dose optimization, and initial anti-tumor activity in patients. CEO Jeffrey Meckler highlighted this as a pivotal step for their Decoy platform, which is anticipated to enhance treatment effectiveness against solid tumors. The first phase will prioritize safety before broader enrollment.
Read more →INDPIndaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported its financial results for Q4 and the fiscal year 2024, providing an update on their Phase 1 trial of Decoy20. The company successfully enrolled more than 20 patients in a weekly dosing cohort, and initial data indicates promising pharmacodynamic immune activation and stable disease in some patients. Additionally, a favorable safety profile has been observed, encouraging further exploration of Decoy20 both as a monotherapy and in combination therapies. There are plans to initiate a combination study with BeiGene's PD-1 inhibitor tislelizumab and to expand trial sites to enhance patient enrollment.
Read more →INDPRegistration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025
Indaptus Therapeutics will host a webinar titled 'Keys To The Kingdom: Unlocking The Power Of Your Immune System' on March 17, 2025. CEO Jeffrey Meckler will present and answer questions from participants. The event aims to highlight the company's advancements in immunotherapy and its unique approach to activating immune responses.
Read more →About Indaptus Therapeutics, Inc.
Headquarters3 COLUMBUS CIRCLE, NEW YORK, NY, 10019
BIOPHARMAWATCH ELITE PLUS
Trade the next INDP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime